coadministered cagrilintide and semaglutide in adults with overweight or obesity Semaglutide, Obesity. June 22,, 2025. DOI: 10.1056/NEJMoa2502081, Cagrilintide–Semaglutide in Adults with, Overweight or and Type 2 We are all anxiously awaiting

Each time you give yourself a shot, thoroughly wash your hands and pick out a clean syringe to use

In vivo animal experiments showed that daily administration of NNMTi for 28 days to dietinduced obese (DIO) mice significantly upregulated the expression of lipolysisrelated genes (such as ATGL and HSL) and downregulated lipogenesisrelated genes (such as FAS and ACC), indicating that NNMTi effectively promotes fat breakdown and inhibits fat synthesis

These effects appear to arise indirectly through vascular support, inflammation control, and cellular protection rather than direct neurotransmitter stimulation

But adjunct therapy on top of a sub-optimal foundation is unlikely to produce the result the patient is looking for, and can produce confusion about what is and is not working

GHK-Cu has an extensive safety record in topical applications and is well-tolerated in injectable protocols at appropriate doses